CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

This trial tests CAR2219, a next-generation CAR T-cell therapy that targets two proteins on leukemia and lymphoma cells (CD19 and CD22) at once, to reduce the chance that cancer cells escape by losing one target. It is designed for patients whose B-cell blood cancers have relapsed or are no longer responding to other treatments. **You may be eligible if...** - You are willing to give informed consent - You have B-cell leukemia or lymphoma (such as B-ALL, CLL, DLBCL, follicular lymphoma, or others) that is relapsed or refractory (come back or stopped responding) - Your cancer cells test positive for CD19 and/or CD22 - You have relapsed within 12 months after first remission, or never achieved remission, or relapsed after prior treatments **You may NOT be eligible if...** - Your cancer has spread to the brain or spinal fluid without treatment - You have severe organ dysfunction - You are pregnant - You have an active, serious infection Talk to your doctor to see if this trial is right for you.